10 October 2024
ProBiotix Health
plc
("ProBiotix" or the "Company"
or, together with its subsidiary, the "Group")
New Commercial Partnership in
Mexico
ProBiotix Health plc (AQSE: PBX),
the life sciences business developing probiotics to support
cardiometabolic health, is pleased to announce a new commercial
partnership with Mexico based raw materials and ingredients
specialist Raff.
Founded in 1999, Raff is a
distributor of raw materials and value-added ingredients, with a
particular focus on the dairy and nutraceutical sectors. Backed by
a highly trained technical team, Raff specialises in the use and
application of lactic and probiotic cultures, rennet, enzymes and
preservatives.
Mexico has a population of 131
million people, with cardiovascular disease the single largest
killer, accounting for nearly 24% of all deaths. Moreover, it is
estimated that around 3.6 million people die in Mexico every year
from high cholesterol. The movement from 'cure' towards
'prevention' provides a strong backdrop for the fast-growing
supplement market, which should lead to a good sales opportunity
for ProBiotix.
The five-year agreement enables Raff
to act in partnership with ProBiotix, as the exclusive distributor
of LPLDL® to be used as an ingredient
for the local manufacturing of finished products. The launch is
planned for the first half of 2025, with commercial sales expected
in late 2025/early 2026.
Steen Andersen, CEO of ProBiotix, commented: "After lengthy discussions
we are delighted to announce our partnership with Raff and firmly
believe that they share our ethos - to develop innovative products
to help enrich individuals with healthier lives.
"The cardiovascular drug market in Mexico is estimated to be
worth $2.2 billion this year, and provides a huge latent
opportunity. With an ageing population, we believe Mexico provides
a highly attractive market for ProBiotix to
target."
Rafael Gonzalez, Commercial Director
of Raff,
added: "As an already well established probiotics supplier in the
Mexican market through our relationship with Italy based Sacco
Systems, having the opportunity to partner with ProBiotix Health,
being a pioneer within probiotics and cardiometabolic health, is
extremely exciting for us.
"We
welcome the opportunity to expand our portfolio with a unique well
documented precision biotic like
LPLDL®. It is our belief that
LPLDL® fills an untapped
potential in the fast growing Mexican supplement market, and that
the product sits well with our already strong position in the
sector."
For
further information, please contact:
|
ProBiotix Health plc
|
https://probiotixhealth-ir.com/
|
|
Steen Andersen, Chief Executive
Officer
|
Contact via Walbrook
below
|
|
|
|
|
Peterhouse Capital Limited (Aquis Corporate Adviser and
Broker)
|
|
|
Mark Anwyl
|
Tel: 020
7220 9793
|
|
|
|
|
Walbrook PR Ltd
|
probiotix@walbrookpr.com
|
|
Anna Dunphy
|
Mob: 07876
741 001
|